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Abstract
Background: Impetigo and scabies are endemic diseases in many tropical countries; however the epidemiology of these
diseases is poorly understood in many areas, particularly in the Pacific.
Methodology/Principal Findings: We conducted three epidemiological studies in 2006 and 2007 to determine the burden
of disease due to impetigo and scabies in children in Fiji using simple and easily reproducible methodology. Two studies
were performed in primary school children (one study was a cross-sectional study and the other a prospective cohort study
over ten months) and one study was performed in infants (cross-sectional). The prevalence of active impetigo was 25.6%
(95% CI 24.1–27.1) in primary school children and 12.2% (95% CI 9.3–15.6) in infants. The prevalence of scabies was 18.5%
(95% CI 17.2–19.8) in primary school children and 14.0% (95% CI 10.8–17.2) in infants. The incidence density of active
impetigo, group A streptococcal (GAS) impetigo, Staphylococcus aureus impetigo and scabies was 122, 80, 64 and 51 cases
per 100 child-years respectively. Impetigo was strongly associated with scabies infestation (odds ratio, OR, 2.4, 95% CI 1.6–
3.7) and was more common in Indigenous Fijian children when compared with children of other ethnicities (OR 3.6, 95% CI
2.7–4.7). The majority of cases of active impetigo in the children in our study were caused by GAS. S. aureus was also a
common cause (57.4% in school aged children and 69% in infants).
Conclusions/Significance: These data suggest that the impetigo and scabies disease burden in children in Fiji has been
underestimated, and possibly other tropical developing countries in the Pacific. These diseases are more than benign
nuisance diseases and consideration needs to be given to expanded public health initiatives to improve their control.
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Introduction
A recent review by the World Health Organization Department
of Child and Adolescent Health and Development indicated that
impetigo and scabies are endemic disease in many tropical and
subtropical countries [1]. This review concluded that more data
documenting the burden of skin disease in children are required at
the community level because of gaps in the evidence, particularly
relating to disease burden in infants and the reporting of incidence
data. The authors of the review also concluded that comparisons
between studies of childhood skin disease are hindered by a lack of
uniform study methodology, particularly standardized case
definitions and the routine inclusion of microbiologic data.
This current study is a comprehensive investigation into the
epidemiology of scabies and impetigo in Fiji. We followed an
epidemiologic protocol developed in 2005 by a World Health
Organization / US National Institutes of Health working group
that is currently being prepared for publication (personal
communication, F Rubin, National Institutes of Health), with
some modifications to suit the Fiji context. We used case
definitions that are simple and provide easily reproducible results.
Our study focused on school-aged children and infants, and
provides prevalence, incidence and microbiologic data.
Methods
Objectives and study design
We conducted three epidemiologic studies in 2006 and 2007 in
order to define the burden of disease of impetigo and scabies in
children in Fiji. The first was a cross-sectional survey in a large
number of primary school children, the second was a prospective
ten month study in a smaller cohort of school children, and the
third was a cross-sectional survey of infants.
Setting
Fiji is a nation of approximately 330 islands located in the
Western Pacific. It has a population of 827,900 people comprising
of two major racial groups of Indigenous Fijians (57.3%) and Indo-
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Fijians (37.6%) [2]. Fiji is ranked 90 out of 177 nations on the
United Nations Development Programme Human Development
Index. It has a GDP per capita of USD6,066 and an infant
mortality rate of 16.8 per 1000 [3,4]. Approximately 49% of the
population lives in rural areas [2]. This study was conducted in
primary schools and child-health centres in the Central Division of
Fiji (population 340,843 people, 75,462 aged 5–14 years) [2].
Primary schools in Fiji extend from class one (five years of age) to
class eight (14 years of age).
Study one. This study was a cross sectional prevalence survey
of school children aged 5–15 years from 21 schools in the Central
Division of Fiji. These schools were chosen by random sampling,
with stratification for geographic location (urban versus rural) and
for ethnicity. Microbiologic specimens were not collected in this
study.
Study two. This was a prospective cohort study performed in
school children aged five to 15 years in three of the 21 schools
included in Study One. These three schools were selected a priori
with the aim of having a closely-followed prospective cohort that
was commensurate to the Indigenous Fijian/Indo-Fijian and
urban/rural proportions of Study One. As such, School A and
school B were Indigenous Fijian schools located in a rural area,
whilst school C was a larger predominantly Indo-Fijian school
located in Fiji’s capital city, Suva. Each school was visited six times
over a ten month period, at two monthly intervals. The
examinations undertaken as part of Study One served as the
first visit in these three schools. Microbiological specimens were
collected at each visit in this study.
Study three. This study was a cross-sectional survey of infants
attending for routine checks at two maternal and child health care
clinics (one rural clinic in proximity to Schools A and B, and one
urban clinic in proximity to School C). Microbiological
confirmation of GAS and S. aureus impetigo was undertaken in
this study.
Study procedures and case definitions
The protocol and case definitions were applied consistently
across all three studies. Children were examined for the clinical
presence of impetigo and scabies, with the initial examination
restricted to the arms, legs, head and neck to avoid embarrass-
ment. Any children with severe scabies or impetigo also had an
examination of the abdomen and back; children did not have an
examination of the buttocks, groin or chest, except in the case of
infants in whom scabies and impetigo lesions are often present in
atypical areas [5]. Research staff were trained in dermatologic
clinical examination, including the clinical diagnosis of impetigo
and scabies, and were supervised by a paediatrician. Active
impetigo was defined as any crusted ulcer or vesiculopustular skin
eruption, whilst old impetigo was defined as any dry skin lesion.
Active impetigo was classified as being mild (less than five lesions),
moderate (between five and 20 lesions) or severe (more than 20
lesions). Where microbiologic data was available, a case of GAS
impetigo was defined as a child with one or more active impetigo
lesions from which GAS was grown from culture of at least one
lesion; Staphylococcus aureus impetigo was defined similarly when S.
aureus was cultured. Scabies was defined on the basis of typical
clinical findings, that is, inflammatory papules with a typical
distribution that were pruritic, without the use of microscopy or
dermatoscopy [6]. Scabies lesions were classified according to
presence of bacterial superinfection (i.e. ‘scabies’ or ‘infected
scabies’).
Treatment. We referred children identified with moderate or
severe impetigo, purulent impetigo or scabies to their local health
clinic for treatment using local guidelines which include oral
flucloxacillin for impetigo and topical benzoyl benzoate for scabies
[7]. This strategy was agreed upon following discussion with the
Fiji Ministry of Health, the relevant health clinics and the ethics
committee in Fiji. Information sheets about skin sores and scabies
written in plain language were provided to the children and their
parents.
Laboratory methods. In Study Two and Study Three,
children identified with vesiculopustular impetigo had a maximum
of two skin swabs taken of impetigo lesions. If two swabs were
taken, they were taken from as distant anatomical sites as possible.
The skin was not cleaned prior to taking a swab. Purulent lesions
were given priority, with swabs of these lesions taken by rolling the
swab over the purulent lesion. If a swab of a crusted impetigo
lesion was taken, this was done by gently lifting the crust and
rolling the swab over the base of the lesion. Skin sore swabs were
transported in a sealed bag containing dessicant and inside a cold
box as described previously [8], and were plated onto sheep blood
within six hours. Following incubation at 37 degrees C in 5% CO2
for up to 24 hours, plates were checked for beta-hemolytic
colonies and the predominant colony on each plate was sub-
cultured onto sheep blood agar and re-grown for Lancefield
grouping (Oxoid, Cambridge, UK). Plates were also checked for
growth of S. aureus based upon colony morphology and confirmed
using Staphaurex (Remel Inc, Kent, UK).
Ethical approval
Ethical approval was obtained from the Fiji National Research
Ethics Review Committee, the Fiji National Health Research
Committee, the University of Melbourne Human Research Ethics
Review Committee, the Queensland Institute of Medical Research
Human Research Ethics Review Committee and the Menzies
School of Health Research Human Research Ethics Review
Committee. Before commencing the study we conducted visits to
the schools to explain the study to students, parents and teachers in
open forums. Information sheets in Fijian and English were
provided to families. Children were only enrolled if written
consent from a parent or guardian was obtained, and in the case of
children aged ten years or older if written assent was also obtained.
Statistical analysis
For the cross-sectional studies, we calculated prevalence of
active impetigo and scabies with binomial 95% confidence
intervals (CI). Logistic regression was used to assess the association
between demographic and clinical factors and the outcome of
interest (presence of active impetigo and scabies). The models
Author Summary
Scabies and impetigo are often thought of as nuisance
diseases, but have the potential to cause a great deal of
morbidity and even mortality if infection becomes
complicated. Accurate assessments of these diseases are
lacking, particularly in tropical developing countries. We
performed a series of studies in infants and primary school
children in Fiji, a tropical developing country in the South
Pacific. Impetigo was very common: more than a quarter
of school-aged children and 12% of infants had active
impetigo. Scabies was also very common affecting 18% of
school children and 14% of infants. The group A
streptococcus was the most common infective organism
followed by Staphylococcus aureus. The size of the problem
has been underestimated, particularly in the Pacific. It is
time for more concerted public health efforts in controlling
impetigo and scabies.
Impetigo and Scabies in Fiji
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accounted for clustering by school and included the following
variables: gender, age, ethnicity, location of school (urban or
rural), body mass index-for-age and either impetigo or scabies.
For the prospective study we calculated point prevalence at each
visit and used a two sample test of proportion to test differences
between prevalence at each visit. We calculated person-time
incidence rates (incidence density), which allowed for calculation
of an incidence rate even if visits were missed. The numerator was
the number of incident cases; an incident case of active impetigo
being defined as a child with an active lesion who did not have any
active lesions at the previous visit (this could occur more than once
for each child). The denominator was the disease-free time at risk
which was the total period of time between consecutive disease-
free visits. We also calculated cumulative incidence (the proportion
of children that became affected by disease during the study
period). The denominator was the number of children that had
complete follow-up and were disease-free at the start of the study,
and the numerator was the number of these children that
developed a new episode of disease during the study period. The
same principles for defining incident cases and calculating
incidence rates were applied to GAS impetigo, S. aureus impetigo
and scabies. When analysing demographic and clinical associa-
tions in the prospective study we used incidence rate ratio
calculations based upon incidence density calculations. The
statistical package STATA version 10.0 (Stata Corporation,
College Station, Texas, USA) was used to analyse the data.
Results
Study one
Of 5562 children invited to participate in this study, 3500 were
enrolled (61.9%), and of these, 38 children were excluded from
further analysis because of their age, making a total of 3462
children aged five to 15 years in the study sample. The median age
of the sample was 10.2 years (interquartile range 8–12.2 years).
There were 2332 Indigenous Fijian Children (67.4%), 969 Indo-
Fijian children (28.0%) and 161 children of other races (4.6%).
There were 1541 children (44.5%) that attended a school located
in a rural area.
Table 1 summarises prevalence figures for impetigo and scabies.
Impetigo was found more commonly on the lower extremities than
the upper limbs (56.0% lower limbs only, 11.9% upper limb only,
32.1% both upper and lower limbs, p,0.001), whilst scabies was
found more commonly on the upper limb (65.8% upper limbs
only, 4.1% lower limb only, 30.1% both upper and lower limbs,
p,0.001).
There was significant variation across the 21 schools; the highest
prevalence of active impetigo by school was 55.8%, and the lowest
was 7.1% with a median of 24.5% , and the highest prevalence of
scabies by school was 42.9% and the lowest was 4.8% with a
median of 12.9%. This variation appeared to be due to ethnicity
and the presence of scabies by school; logistic regression analysis of
demographic factors revealed Indigenous Fijian race and the
presence of scabies to be significantly associated with active
impetigo (Table 2). Children aged six years were at greatest risk of
active impetigo and scabies, with a prevalence of active impetigo
and scabies in this group of 33.9% (95% CI 29–39.1) and 26.6%
(95% CI 22.0–21.5) respectively.
Study two
Of the 685 children eligible for the study, 457 children (66.7%)
were enrolled; 80 children at school A (enrolment rate 96.4%), 175
at school B (80.6%) and 202 at school C (53.2%). There were 322
Indigenous Fijian Children (70.5% of sample), 99 Indo-Fijian
children (21.7%) and 36 children of other races (7.8%). Just over
half of the enrolled children attended one of the two rural schools
(n = 255, 55.8%) and all of these children were Indigenous Fijian.
The median age of the sample was 9.9 years (interquartile range
7.9–12 years). All 457 children enrolled into the study were seen at
the initial visit, and of these, 378 children were seen at all six visits;
42 children were seen on five occasions, six children on four
occasions, three children on three occasions, six children on two
occasions visits and 22 children were seen only at the first visit. In
total there were 2545 examinations performed, and a total of
114667 child-days of observation (314 years).
Prevalence. Of the 457 children seen at the first visit, 187
had active impetigo (prevalence 40.9%, 95% CI 36.4–45.6), 95
had GAS impetigo (prevalence 20.8%, 95% CI 17.2–24.8) and
105 had scabies (prevalence 23.0%, 95% CI 19.2–27.1). The
prevalence of impetigo and scabies varied by school and by visit
(Figure 1). The prevalence of active impetigo reduced by 67.7% at
the second visit to a prevalence of 27.7% (95% CI 23.6–32.2,
p,0.0001) and this significant reduction was sustained throughout
the period of the study (prevalence at last visit 25.7%, 95% CI
21.5–30.3, p,0.0001). The prevalence of GAS impetigo
decreased at the second visit to a prevalence of 16.6% (95% CI
13.2–20.4, p = 0.11), and although this reduction was not
significant, further reductions occurred so that the prevalence at
the final visit fell by 50.9% when compared with the first visit
(prevalence 10.6%, 95% CI 7.7–14.0, p,0.001). The prevalence
of scabies reduced by 57.8% at the second visit to a prevalence of
13.3% (95% CI 10.2–16.9, p,0.001), however this reduction was
Table 1. Prevalence of scabies and impetigo in 3462 primary school children (CI: confidence interval).
Total 5–8 years 9–11 years 12–15 years
n
Prevalence
(%) 95% CI n
Prevalence
(%) 95% CI n
Prevalence
(%) 95% CI n
Prevalence
(%) 95% CI
Impetigo All 1259 36.4 34.8–38.0 372 42.9 39.6–46.2 449 37.9 35.1–40.7 438 31.1 28.6–33.5
Active 885 25.6 24.1–27.1 268 30.9 27.8–34.1 329 27.8 25.2–30.4 288 20.4 18.3–22.6
Mild 640 18.5 17.2–19.8 195 22.5 19.7–25.3 221 18.6 16.4–20.9 244 15.9 14.0–17.8
Moderate 182 5.3 4.5–6.1 48 5.5 4.0–7.1 82 6.9 5.5–8.4 52 3.7 2.7–4.7
Severe 63 1.8 1.4–2.3 25 2.9 1.8–4.0 26 2.2 1.4–3.0 12 0.9 0.4–1.3
Scabies All 640 18.5 17.2–19.8 213 24.6 21.7–27.6 213 18.0 15.8–20.3 214 15.2 13.3–17.2
Infected 191 5.5 4.5–6.3 65 7.5 5.7–9.3 67 5.7 4.3–7.0 59 4.2 3.1–5.2
doi:10.1371/journal.pntd.0000467.t001
Impetigo and Scabies in Fiji
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not maintained throughout the study period (prevalence at last
visit 20.1%, 95% CI 16.3–24.4, p = 0.3).
Incidence density and cumulative incidence. Table 3
summarizes incidence density data for active impetigo, GAS
impetigo, S. aureus impetigo and scabies. Of the 378 children that
had full follow-up (that is, 6 visits), there were 219 (57.9%) that
were free of active impetigo at the start of the study. Of these, 104
children (47.5%) had at least one new episode of during the course
of the study. For GAS impetigo, S. aureus impetigo and scabies,
36.7%, 32.9% and 24.6% of disease free children at the start of the
study had a new episode of disease respectively.
Because scabies is characterized by ongoing infestation we
analysed data relating to the number of children that had scabies
found at more than one visit. Of the 378 children that had full
follow-up, there were nine who had scabies at all six visits, nine at
five visits, 10 at four visits, 16 at three visits and 36 at two visits.
Demographic analysis. Analysis of demographic data
revealed that incidence rates of GAS impetigo and scabies were
Table 2. Tests of association for the prevalence of active impetigo and scabies in children aged 5–15 years at 21 primary schools
Fiji.
Factor Total Active impetigo Scabies
n
Prevalence as
percentage (95% CI)
Odds ratio*
(95% CI) n
Prevalence as
percentage (95% CI)
Odds ratio*
(95% CI)
Gender Male 1692 532 31.4 (29.2–33.7) 1.9 (1.6–2.2) 326 19.3 (17.4–21.2) 1.0 (0.8–1.2)
Female 1770 353 19.9 (18.1–21.9) 314 17.7 (16.0–19.6)
Ethnicity Fijian 2332 770 33.0 (31.1–35.0) 3.6 (2.7–4.7) 587 25.2 (23.4–27.0) 4.8 (2.5–9.4)
Other 1130 115 10.2 (8.5–12.1) 53 13.5 (11.6–15.7)
Location of school Rural 1541 481 31.2 (28.9–33.6) 1.1 (0.6–2.0) 376 24.4 (22.3–26.6) 1.3 (0.7–2.3)
Urban 1921 404 21 (19.2–22.9) 264 13.7 (12.2–15.4)
Age 5–8 years 867 268 30.9 (27.8–34.1) 0.91 (0.87–0.94){ 213 24.6 (21.7–27.6) 0.91 (0.87–0.96){
9–11 year 1185 329 27.8 (25.2–30.4) 213 18.0 (15.8–20.3)
12–15 years 1410 288 20.4 (18.3–22.6) 214 15.2 (13.3–17.2)
Active impetigo Impetigo 885 - - - 300 33.9 (30.8–37.1) 2.2 (1.5–3.2)
No impetigo 2577 - - 340 13.2 (11.9–14.6)
Scabies Scabies 640 300 46.9 (43.0–50.8) 2.4 (1.6–3.7) - - -
No scabies 2822 585 20.7 (19.2–22.3) - -
Overall 3462 885 25.6 (24.1–27.1) 640 18.5 (17.2–19.8)
*Odds ratios were calculated using a logistic regression model.
{Odds ratios for age were calculated using age as a continuous variable in the logistic regression model.
doi:10.1371/journal.pntd.0000467.t002
Figure 1. Prevalence of skin disease by school and by visit over a period of 10 months at three primary schools in Fiji.
doi:10.1371/journal.pntd.0000467.g001
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significantly higher in Indigenous Fijian children (incidence rate
ratio for GAS impetigo 4.5, 95% CI 2.9–7.8, and incidence rate
ratio for scabies 3.4, 95% 2.0–6.2). Children aged 5–9 years had a
higher incidence of GAS impetigo and scabies than children aged
10–14 years (incidence rate ratio for GAS impetigo 1.6, 95% CI
1.2–2.1, and incidence rate ratio for scabies 2.2, 95% CI 1.5–3.2).
Microbiology. A total of 563 swabs were taken from 455
children (108 children had two swabs taken) and there was
bacterial growth from 522 swabs (92.7%). There was growth of
beta-hemolytic streptococci from 491 swabs (87.2%). GAS was
isolated from 449 swabs (79.8% of all swabs), GGS from 28 swabs
(5.0%), GCS from 11 swabs (2.0%), GBS from one swab, and two
isolates were not able to be characterized by carbohydrate
grouping. S. aureus was isolated from 323 swabs (57.4%) and
co-existed with beta-hemolytic streptococci in 292 swabs (51.9%),
of which 265 were GAS (47.1% of total).
Of the 108 children that had two swabs taken, 85 had BHS
isolated from both swabs, of which 77 children had GAS isolated
from both swabs, one child had GGS isolated from both swabs,
whilst eight children had a GAS isolated from one swab and a
GGS isolated from the other swab. Of the 77 children with GAS
isolated from both swabs, 60 children were found to have the same
emm type of GAS in both swabs.
Study three
There were 451 infants enrolled in this study, divided between
the rural and urban clinics (rural clinic n= 226, urban clinic
n = 225). The median age of the sample was 20 weeks of age
(interquartile range 8–37 weeks), and 265 children were aged six
months or less (58.8%). There were 304 Indigenous Fijian
Children (67.4%), 111 Indo-Fijian children (24.6%) and 36
children of other races (8.0%).
Table 4 summarises prevalence data for impetigo and scabies in
infants. There was no clear association between impetigo and
distribution on the upper or lower limbs (37% lower limbs only,
13% upper limb only, 50% both upper and lower limbs, p = 0.15).
Scabies was more commonly found on the lower extremities
(39.7% lower limbs only, 9.5% upper limb only, 50.8% both upper
and lower limbs, p= 0.04). In the logistic regression model there
was a clear association between GAS impetigo and scabies (OR
36.9, 95% CI 16.9–80.7).
Microbiology. A total of 61 swabs were taken from 50 infants
(11 infants had two swabs taken), and there was bacterial growth
from 52 swabs (85%). There was growth of beta-hemolytic
streptococci from 41 swabs (67%), and GAS was isolated from 30
swabs (49% of total number of swabs), GGS from eight swabs
(13%), GCS from two swabs and GBS from one swab. S. aureus
was isolated from 42 swabs (69%) and co-existed with beta-
hemolytic streptococci in 31 swabs (51%), of which 23 were GAS
(38% of total).
Discussion
Our study indicates that there is a large burden of skin disease in
children in Fiji. Over one quarter of school aged children in our
cross-sectional study had active impetigo at any given time and
almost half of impetigo-free children in our prospective cohort
study experienced a new episode of active impetigo during the ten
month study period. Nearly one-third of scabies-free children in
the cohort experienced a new episode of scabies during the study
period. Impetigo and scabies were also highly prevalent diseases in
the infants observed in our study, although less common than in
children. The majority of cases of active impetigo in the children
in our study were caused by GAS (79.8% in school aged children,
and 49% in infants), although S. aureus was also a common cause
(57.4% in school aged children and 69% in infants).
A recent review of the prevalence of childhood skin diseases in
developing tropical and subtropical countries concluded that the
Table 3. Incidence density of new cases of active impetigo, group A streptococcal (GAS) impetigo, Staphylococcus aureus (SA)
impetigo and scabies in three Fijian schools.
Disease free days New cases Incidence per 100 child-years 95% confidence interval
Active impetigo 83,132 277 122 108–137
GAS impetigo 96,447 212 80 75–85
SA impetigo 100,444 175 64 55–74
Scabies 97,580 136 51 43–60
doi:10.1371/journal.pntd.0000467.t003
Table 4. Prevalence of scabies and impetigo in 451 infants (CI: confidence interval).
Total 0–6 months 7–12 years
n Prevalence (%) 95% CI n Prevalence (%) 95% CI n Prevalence (%) 95% CI
Impetigo All 60 13.3 10.3–16.8 16 6.0 3.2–8.9 44 23.7 17.5–29.8
Active 55 12.2 9.3–15.6 13 4.9 2.3–7.5 42 22.6 16.5–28.6
Mild 38 8.4 6.0–11.4 11 4.2 1.7–6.6 27 14.5 9.5–19.6
Moderate 8 1.8 0.8–3.5 1 0.4 0–1.1 7 3.8 1.0–6.5
Severe 9 2.0 0.8–3.8 1 0.4 0–1.1 8 4.3 1.4–7.2
Scabies All 63 14.0 10.7–17.2 24 9.1 5.6–12.5 39 21.0 15.1–26.9
Infected 36 8.0 5.5–10.5 8 3.0 0.9–5.1 28 15.1 9.9–20.2
doi:10.1371/journal.pntd.0000467.t004
Impetigo and Scabies in Fiji
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prevalence of impetigo is commonly in the range of 5–10% and
the prevalence of scabies is in the range of 1–2% [1]. Many of the
studies included in this review were from sub-Saharan Africa.
Studies from the Pacific, including ours, suggest that the
prevalence of impetigo and scabies is significantly higher in the
Pacific region [9,10,11,12]. The reason for this is not clear. A
significant finding in our study was the higher risk of GAS
impetigo and scabies in Indigenous Fijian children.
We have previously noted higher rates of GAS disease in
Indigenous Fijians, including invasive GAS disease and rheumatic
heart disease [13,14]. Other investigators have noted higher rates
of other Gram-positive infections, including radiographically
proven pneumonia [15].
We used a simple method to calculate incidence density and
found a very high incidence density of new cases active impetigo
and scabies. It is likely that our figures are in fact an underestimate
of the true incidence for three reasons. First, we may have missed
new cases of impetigo and scabies that erupted and then healed in
between the two-monthly study visits. A study in Mali estimated
that 41% and 53% of cases of impetigo and scabies lasted for less
than one month respectively [16]. Second, we required a child to
be disease-free at the previous visit before a case could be counted
as a new case; we therefore did not count new lesions in children
with existing lesions as incident cases – to detect these cases would
require more intensive surveillance techniques such as interval
photography. Third, the method of clinical examination in this
study may have underestimated prevalence because the entire
body was not always examined. There were also other limitations
to our study including potential sources of bias. There was the
potential for participation bias because of differing enrolment rates
between schools and between studies, and there was also the
potential for inter-rater variability and bias because of multiple
observers, although we attempted to standardize the clinical
examination methodology as much as possible.
Impetigo and scabies have been considered public health
problems in developing countries for decades [16,17], however
there has been little progress in their control on a global scale
[1,18]. It is estimated that there are more than 111 million
prevalent cases of GAS pyoderma globally [19]. Although often
considered as a benign disease, impetigo can lead to more serious
illnesses including cellulitis and abscess via local spread, bacter-
emia and sepsis following haematogenous invasion, as well as the
non-suppurative sequelae of acute post-streptococcal glomerulo-
nephritis and possibly acute rheumatic fever [20]. The highest
incidence rates of invasive GAS disease have been described in
tropical developing countries and impetigo has been identified as
an important portal of entry [13,21,22]. The mortality rate from
invasive GAS disease in these settings is high; in Fiji the all-ages
case fatality rate is over 25% [13]. Post-streptococcal glomerulo-
nephritis in tropical regions almost always follows impetigo GAS
infection rather than GAS pharyngitis as it does in industrialised
countries [23,24,25]. There is evidence to suggest that acute post-
streptococcal glomerulonephritis may contribute to chronic renal
impairment in adult life [26]. Scabies on its own can cause
significant clinical impact, most notably sleep disturbance that
occurs in up to 70% of cases [5]. In addition to their clinical
impact, impetigo and scabies also cause a considerable financial
burden to individuals, families and health services. From the
limited published data, impetigo and scabies account for between
12.3% and 23.7% of primary health care centre presentations in
tropical countries, placing a significant drain on these services [1].
Impetigo and scabies leads to absence from school and costly
treatment. In a study in Mexico, the average period of absence
from school for scabies was 8 days and for pyoderma 15 days, and
the average cost of treatment for scabies and impetigo was US$24
and US$52 respectively [1,27].
Given the clinical and economic burden of impetigo and
scabies, and the sheer volume of cases in tropical developing
countries, there have been renewed appeals for an organized
global effort to control these diseases [1]. However, in many
countries where impetigo and scabies are common, there are
competing health problems that carry higher morbidity and
mortality. Therefore, it has been suggested that control measures
be simple, practical, of low cost and commensurate with the
level of the priority of the problem in the local context [1]. We
have recently validated an algorithm for the identification and
treatment of common childhood skin conditions that can be
incorporated into existing Integrated Management of Childhood
Illness programs [28]. This algorithm is designed to improve
case management of childhood skin diseases at the primary
health care level, with minimal need for additional infrastructure
and training.
In countries such as Fiji that have been able to significantly
reduce high mortality diseases and in which skin disease is
common, it may be appropriate to consider initiatives aimed at
controlling impetigo and scabies on a broader public health level.
Whilst mass drug treatment with scabicides can produce short-
term reduction in scabies disease burden [29], most experts believe
that a sustained reduction requires an integrated approach that
includes the following elements: public health education, improved
case management, improved drug supply and potentially im-
provements in personal hygiene practices [18,30]. Intervention
studies in the Pacific region aimed solely at scabies control have
been shown to achieve their aim of controlling scabies with a flow-
on effect on scabies-associated impetigo, but they have had less
effect on non-scabies impetigo [10,31]. The finding of a large
burden of impetigo independent of scabies in school-aged children
in our study suggests that the case may be the same in Fiji [9,11].
Further research into practicable, effective and sustainable control
measures is required.
A GAS vaccine could also be an important advance in primary
prevention of impetigo. However, major questions remain about a
GAS vaccine designed to prevent skin disease. First, little is known
about the mechanism of immunoprotection against impetigo
[32,33], because group A streptococcal vaccine research has
largely focused on protection against pharyngitis and invasive
disease. Second, it is not clear what effect a GAS vaccine would
have on S. aureus in impetigo lesions. As we have shown, S. aureus is
a common infecting agent in impetigo, and S. aureus and GAS can
co-exist in individual lesions. It is possible that circulating GAS
strains removed by a vaccine would only be replaced by S. aureus
strains that are currently the victims of competitive inhibition by
GAS. Third, the design of a GAS vaccine against skin disease
would need to be specifically tailored to cover common types of
GAS that cause impetigo.
Our study confirms that impetigo and scabies are endemic
diseases in Fiji causing a substantial disease burden, consistent
with findings from around the region. These findings, coupled
with the potential for clinical complications and a heavy socio-
economic impact, suggest that it is time for more concerted
action against these diseases in Fiji and other tropical developing
nations.
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